


RC-3095 TFA

Cat. No.: HY-P0107A
CAS No.: 1217463-61-0
Molecular Formula: C₅₈H₈₀F₃N₁₅O₁₁
Molecular Weight: 1220.34
Target: Bombesin Receptor
Pathway: GPCR/G Protein
Storage: Sealed storage, away from moisture

Powder -80°C 2 years
 -20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H₂O : 40 mg/mL (32.78 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		0.8194 mL	4.0972 mL	8.1944 mL
	5 mM		0.1639 mL	0.8194 mL	1.6389 mL
	10 mM		0.0819 mL	0.4097 mL	0.8194 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

RC-3095 TFA is a selective bombesin/gastrin releasing peptide receptor (GRPR) antagonist^[1]. RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice^[2].

IC₅₀ & Target

Bombesin receptor; GRPR^[1]

In Vivo

RC-3095 impairs aversive but not recognition memory in Wistar male rats^[1].
 RC-3095 (0.3 mg/kg or 1 mg/kg; S.C.) shows anti-inflammatory effects in 2 experimental models of arthritis, collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA)^[2].
 Arthritic mice treated with RC-3095 show a significant reduction in the concentrations of IL-17, IL-1, and TNF, and showed a diminished expression of GRPR^[2].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Balb/c wild-type mice (weighing 18-25 gm) with AIA model; Male DBA/1J inbred mice (weighing 18-25 gm) with CIA model^[2]

Dosage:	1 mg/kg for AIA studies; 0.3 mg/kg or 1 mg/kg for CIA studies
Administration:	Injected SC twice a day for a total of 2 or 10 days for AIA studies; Administered SC twice a day for 10 days after the onset of the disease for CIA studies
Result:	Reduced neutrophil migration, mechanical hy pernociception, and proteoglycan loss in mice with AIA; Led to a significant reduction in arthritis clinical scores and the severity of disease in the CIA model.

REFERENCES

- [1]. Oliveira PG, et al. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Arthrit
- [2]. Roesler R, et al. RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol. 2004 Feb 13;486(1):35-41.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA